8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pathological angiogenesis: mechanisms and therapeutic strategies

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In multicellular organisms, angiogenesis, the formation of new blood vessels from pre-existing ones, is an essential process for growth and development. Different mechanisms such as vasculogenesis, sprouting, intussusceptive, and coalescent angiogenesis, as well as vessel co-option, vasculogenic mimicry and lymphangiogenesis, underlie the formation of new vasculature. In many pathological conditions, such as cancer, atherosclerosis, arthritis, psoriasis, endometriosis, obesity and SARS-CoV-2(COVID-19), developmental angiogenic processes are recapitulated, but are often done so without the normal feedback mechanisms that regulate the ordinary spatial and temporal patterns of blood vessel formation. Thus, pathological angiogenesis presents new challenges yet new opportunities for the design of vascular-directed therapies. Here, we provide an overview of recent insights into blood vessel development and highlight novel therapeutic strategies that promote or inhibit the process of angiogenesis to stabilize, reverse, or even halt disease progression. In our review, we will also explore several additional aspects (the angiogenic switch, hypoxia, angiocrine signals, endothelial plasticity, vessel normalization, and endothelial cell anergy) that operate in parallel to canonical angiogenesis mechanisms and speculate how these processes may also be targeted with anti-angiogenic or vascular-directed therapies.

          Related collections

          Most cited references394

          • Record: found
          • Abstract: found
          • Article: not found

          Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

          The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

            The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

              The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.
                Bookmark

                Author and article information

                Contributors
                acd2g@virginia.edu
                a.griffioen@amsterdamumc.nl
                Journal
                Angiogenesis
                Angiogenesis
                Angiogenesis
                Springer Netherlands (Dordrecht )
                0969-6970
                1573-7209
                15 April 2023
                15 April 2023
                : 1-35
                Affiliations
                [1 ]GRID grid.27755.32, ISNI 0000 0000 9136 933X, Department of Microbiology, Immunology and Cancer Biology, , The University of Virginia, ; Charlottesville, VA 22908 USA
                [2 ]GRID grid.16872.3a, ISNI 0000 0004 0435 165X, Angiogenesis Laboratory, Department of Medical Oncology, , Amsterdam UMC, Cancer Center Amsterdam, ; Amsterdam, The Netherlands
                Article
                9876
                10.1007/s10456-023-09876-7
                10105163
                37060495
                197e6a38-d46b-40d6-b4e0-f385d5ea51d0
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 7 February 2023
                : 26 March 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100004622, KWF Kankerbestrijding;
                Award ID: VU2018–11651
                Award Recipient :
                Categories
                Review Paper

                Human biology
                angiogenesis,anti-angiogenesis,vascular biology,vascular targeting,endothelial cells,immunotherapy

                Comments

                Comment on this article